SEARCH
検索詳細
山崎 博之 (ヤマザキ ヒロユキ)
| 北海道大学病院 小児・周産・女性科 | 助教 |
研究者基本情報
■ 学位■ URL
researchmap URLホームページURL■ ID 各種
研究者番号
- 70980407
研究分野
研究活動情報
■ 論文- Feasibility study of photoimmunotherapy combination with ASP-1929 for vulvar, vaginal, and cervical cancer.
Ryutaro Yamamoto; Hiroshi Asano; Kanako C Hatanaka; Yoshiki Shinomiya; Hiroyuki Yamazaki; Hiroko Matsumiya; Michiko Nagamine; Yuko Sasajima; Yutaka Hatanaka; Hidemichi Watari
Journal of gynecologic oncology, 2026年05月21日, [国際誌]
英語, 研究論文(学術雑誌), OBJECTIVE: The aim of this study was to evaluate the feasibility of photoimmunotherapy (PIT) using ASP-1929, an anti-epidermal growth factor receptor (EGFR) antibody-dye conjugate, for vulvar, vaginal, and cervical cancers by validating EGFR expression and establishing immunohistochemistry (IHC)-based eligibility criteria for a phase II trial, HICARi study. METHODS: Cetuximab-binding activity was analyzed in gynecologic cancer cell lines (CaSki, HeLa, and Ishikawa) using flow cytometry and compared with positive controls (A431 and BxPC-3) and a low-EGFR control (MCF-7). IHC was performed on cell blocks and clinical specimens of vulvar, vaginal, and cervical cancers (validation cohort, n=27; screening cohort, n=40). RESULTS: CaSki demonstrated comparable or higher EGFR binding than BxPC-3, whereas HeLa and Ishikawa showed weaker binding. IHC staining intensity correlated with flow cytometry findings. Squamous cell carcinomas consistently exhibited moderate-to-strong EGFR expression, whereas non-squamous carcinomas displayed variable expression. EGFR positivity was defined as >30% of tumor cells with at least moderate membranous staining (2+ or 3+). In the validation cohort, EGFR positivity was observed in 71.4% of the vulvar, 80.0% of the vaginal, and 87.5% of the cervical cancers. The screening cohort showed similar rates: 88.9% of vulvar, 100% of vaginal, and 75.0% of cervical cancers. CONCLUSION: We demonstrated correlation between cetuximab-binding and IHC staining intensity, establishing IHC criteria (≥2+) for patient selection. EGFR positivity (71.4%-87.5%) indicates substantial eligibility for ASP-1929 PIT. Therapeutic efficacy will be evaluated in the HICARi study. - Hokkaido phase II study of photo-immunotherapy combination with ASP-1929 for recurrent or persistent EGFR-positive vulvar, vaginal, and cervical cancers not amenable to further radiotherapy (HICARi study).
Hiroshi Asano; Hiroyuki Yamazaki; Hiroko Matsumiya; Isao Yokota; Kazufumi Okada; Ryutaro Yamamoto; Kanako C Hatanaka; Yuko Sasajima; Michiko Nagamine; Yutaka Hatanaka; Fumi Kato; Junko Takahama; Takahiro Tsuboyama; Yudai Watanabe; Naoko Okita; Hidemichi Watari
Journal of gynecologic oncology, 2026年05月18日, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Photoimmunotherapy using ASP-1929 (ASP1929-PIT) is a novel approach targeting epidermal growth factor receptor (EGFR)-expressing tumors. ASP-1929, an anti-EGFR monoclonal antibody conjugated to IRDye 700DX (IR700), binds to EGFR in tumor cells. Upon exposure to 690-nm red laser light, IR700 is activated, disrupting the cellular membrane. Approved in Japan for head and neck cancer, this therapy is the first of its kind globally. Given its mechanism, ASP-1929 may also treat other EGFR-positive malignancies accessible to red light. Thus, we are conducting a phase II clinical trial of ASP1929-PIT for localized recurrent and persistent vulvar, vaginal, and cervical cancers refractory to radiotherapy (RT). These severely impact quality of life, highlighting an unmet need. METHODS: This single-arm, open-label, phase II investigator-initiated trial evaluated the efficacy and safety of ASP1929-PIT for recurrent or persistent vulvar, vaginal, or cervical cancer post-RT (jRCT2011240034). Participants had EGFR expression confirmed by immunohistochemistry, prior RT (including chemoradiotherapy) for the primary lesion, and at least one measurable vulvar, vaginal, or cervical lesion. Patients with uncontrolled distant disease or suspected mucosal invasion of the rectum or lower urinary tract were excluded. ASP-1929 (640 mg/m²) was administered via a 2-hour intravenous infusion, followed 20-28 hours later by 690-nm laser illumination. Day 1 was designated for ASP-1929 administration, with efficacy assessed between days 29 and 56. Patients could receive up to three additional treatments if a complete response was not achieved. The primary outcome was tumor shrinkage in laser-treated lesions. Sixteen patients were enrolled, with the first 4 forming a safety cohort. TRIAL REGISTRATION: Japan Registry of Clinical Trials Identifier: jRCT2011240034. - The prognosis of endometrial cancers stratified with conventional risk factors and modified molecular classification
Hiroyuki Yamazaki; Hiroshi Asano; Kanako C. Hatanaka; Ryosuke Matsuoka; Yosuke Konno; Yoshihiro Matsuno; Yutaka Hatanaka; Hidemichi Watari
Cancer Science, 2022年09月
研究論文(学術雑誌) - Comparison between Urine and Cervical High-Risk HPV Tests for Japanese Women with ASC-US
Hiroyuki Yamazaki; Tsuneyuki Wada; Hiroshi Asano; Hiromasa Fujita; Kazuhira Okamoto; Hidemichi Watari
Diagnostics, 2021年10月14日
研究論文(学術雑誌) - The difficulty to diagnose cervical cancer developing in the perinatal period with the first‐trimester cytology: A retrospective study
Hiroyuki Yamazaki; Takashi Mitamura; Kei Ihira; Daisuke Endo; Manami Sakurai; Yosuke Konno; Hidemichi Watari
Journal of Obstetrics and Gynaecology Research, Wiley, 2021年06月09日
英語, 研究論文(学術雑誌) - Imaging-based definition of lower uterine segment carcinoma to improve the detection sensitivity of probable Lynch syndrome.
Hiroyuki Yamazaki
Japanese journal of clinical oncology, 2020年03月01日
研究論文(学術雑誌), OBJECTIVE:The aim of this study was to investigate a magnetic resonance imaging-based definition of lower uterine segment carcinoma. METHODS:We retrospectively reviewed 587 consecutive patients with endometrial cancer who underwent hysterectomy. Lower uterine segment carcinoma was determined through pathological examination and magnetic resonance imaging assessment. For imaging assessment, the location of the inner lining of the uterus was classified into four equal parts on a sagittal section image. A tumor was defined as lower uterine segment carcinoma when its thickest part was located in the second or the third part from the uterine fundus. Lower uterine segment carcinoma was further divided into lower uterine segment in a narrow sense, upon which diagnosis was exclusively based on pathological findings, and lower uterine segment in a broad sense that were the remaining lower uterine segment carcinomas except lower uterine segment carcinomas in a narrow sense. The relationship between lower uterine segment carcinoma and probable Lynch syndrome was investigated. Patients with loss of MSH2, MSH6, and PMS2 expression or those with tumors with loss of MLH1 and absence of MLH1 promoter methylation were diagnosed as probable Lynch syndrome. RESULTS:Lower uterine segment carcinoma was identified in 59 (10.2%) patients. Twenty-eight (47.5%) patients were categorized as lower uterine segment in a narrow sense and 31 (52.5%) as lower uterine segment in a broad sense. Among them, probable Lynch syndrome was identified in 12 (20.3%) cases. There was no difference in clinical profiles, including the prevalence of probable Lynch syndrome between the two categories. CONCLUSIONS:A magnetic resonance imaging-based expanded definition of lower uterine segment carcinoma is likely to secure characteristics equivalent to a conventional pathology-based definition of lower uterine segment carcinoma. The novel definition of lower uterine segment carcinoma might improve the detection of probable Lynch syndrome. - Therapeutic significance of full lymphadenectomy in early-stage ovarian clear cell carcinoma
Hiroyuki Yamazaki; Yukiharu Todo; Chisa Shimada; Sho Takeshita; Shinichiro Minobe; Kazuhira Okamoto; Katsushige Yamashiro; Hidenori Kato
Journal of Gynecologic Oncology, 29, 2, Asian Society of Gynecologic Oncology$\mathsemicolon$ Korean Society of Gynecologic Oncology and Colposcopy ({KAMJE}), 2018年
研究論文(学術雑誌) - A prediction model of survival for patients with bone metastasis from uterine cervical cancer
Hiroko Matsumiya; Yukiharu Todo; Kazuhira Okamoto; Sho Takeshita; Hiroyuki Yamazaki; Katsushige Yamashiro; Hidenori Kato
Journal of Gynecologic Oncology, 27, 6, Asian Society of Gynecologic Oncology$\mathsemicolon$ Korean Society of Gynecologic Oncology and Colposcopy ({KAMJE}), 2016年
研究論文(学術雑誌) - Relationship between removal of circumflex iliac nodes distal to the external iliac nodes and postoperative lower-extremity lymphedema in uterine cervical cancer.
Hiroyuki Yamazaki
Gynecologic oncology, 2015年09月10日
研究論文(学術雑誌),Objective
This study aimed to determine if there is a causal relationship between removal of the circumflex iliac nodes distal to the external iliac nodes (CINDEIN) and postoperative lower-extremity lymphedema (POLEL) after systematic lymphadenectomy in patients with cervical cancer.Methods
A retrospective chart review was performed for all living cervical cancer patients who underwent lymphadenectomy and were managed at Hokkaido Cancer Center between 1993 and 2013. The type of lymphadenectomy gradually shifted from lymphadenectomy with removal of CINDEIN to without CINDEIN dissection during this period. The study period was divided into two phases: from 1993-2007 (first phase) and from 2008-2013 (second phase). We identified patients with POLEL. Logistic regression analysis was used to select the risk factors for POLEL.Results
Implementation of CINDEIN-dissection lymphadenectomy (94.0% vs. 20.6%, p<0.0001) and adjuvant radiotherapy (26.1% vs. 4.5%, p<0.0001) was significantly higher in the first phase than in the second phase. Of 398 patients evaluated, POLEL was noted in medical records of 80 (20.1%) patients with a median follow-up period of 78.0months. The occurrence rate of POLEL was significantly higher in the first phase than in the second phase (32.2% vs. 8.0%, p<0.0001), despite no change in the number of dissected lymph nodes between the two phases. Multivariate analysis showed that adjuvant radiation therapy (odds ratio=2.6, 95% confidence interval=1.4-4.8) and removal of CINDEIN (odds ratio=4.6, 95% confidence interval=2.4-9.0) were independent risk factors for POLEL.Conclusion
Elimination of CINDEIN dissection is helpful for reducing the incidence of POLEL. - Pretreatment risk factors for parametrial involvement in FIGO stage IB1 cervical cancer.
Hiroyuki Yamazaki
Journal of gynecologic oncology, 2015年07月14日
研究論文(学術雑誌),Objective
All patients with stage IB1 cervical cancer do not need to undergo parametrectomy. Some low-risk criteria for parametrial involvement (PI) have been proposed based on pathological findings. The aim of this study was to determine pretreatment risk factors for PI in stage IB1 cervical cancer.Methods
We retrospectively reviewed 115 patients with stage IB1 cervical cancer who underwent radical hysterectomy or radical trachelectomy. Magnetic resonance imaging (MRI) was performed and serum concentrations of squamous cell carcinoma antigen (SCC-Ag) and cancer antigen 125 (CA-125) were determined in all patients before initial treatment. The following pretreatment factors were investigated: histological variant, maximum tumor diameter, tumor volume (volume index), pelvic lymph node enlargement, and serum tumor markers. Logistic regression analysis was used to select the independent risk factors for PI.Results
Eighteen of the 115 patients (15.7%) were pathologically diagnosed with PI. Multivariate analysis confirmed the following independent risk factors for PI: MRI-based tumor diameter ≥ 25 mm (odds ratio [OR], 9.9; 95% confidence interval [CI], 2.1 to 48.1), MRI-based volume index ≥ 5,000 mm³ (OR, 13.3; 95% CI, 1.4 to 125.0), and positive serum tumor markers SCC-Ag ≥ 1.5 ng/mL or CA-125 ≥ 35 U/mL (OR, 5.7; 95% CI, 1.3 to 25.1). Of 53 patients with no risk factors for PI, none had PI.Conclusion
Less radical surgery may become one of the treatment options for stage IB1 cervical cancer patients with MRI-based tumor diameter <25 mm, MRI-based volume index <5,000 mm³, and negativity for SCC-Ag and CA-125.
- 腟式細切により子宮を回収した電動モルセレーターを使用しないTLH後に発生した異所性子宮筋腫の1例
石塚 泰也; 工藤 正尊; 大原 康弘; 山崎 博之; 井平 圭; 宇田 智浩; 中谷 真紀子; 加藤 達矢; 渡利 英道; 櫻木 範明, 日本産科婦人科内視鏡学会雑誌, 33, 1, 131, 137, 2017年04月
46歳(1経妊1経産)。子宮平滑筋腫に対する電動セルモーターを使用しない腹腔鏡下子宮全摘出術後59ヵ月目の定期検診にて腟断端右端の腫瘤影を指摘された。各種検査結果と手術歴から異所性子宮筋腫(PM)を第一に疑い、審査腹腔鏡となった。腹腔鏡所見では腟断端右端に相当する部位に後腹膜腔内に発育する6cm大の腫瘤性病変を認めたが、腸管との連続性はなかった。また、腟断端左側に同様の腫瘤が2個認められた。1個の腫瘤を摘出し、病理組織学的にPMと診断されたため、後日、腹腔鏡下に残りの腫瘤を摘出した。最終手術から1年経過現在、再発はみられていない。, (一社)日本産科婦人科内視鏡学会, 日本語 - 子宮頸癌に対する広汎子宮全摘術後の補助化学療法の有用性についての後方視的検討
嶋田 知紗; 加藤 達矢; 朝野 拓史; 山崎 博之; 井平 圭; 遠藤 大介; 福本 俊; 宇田 智浩; 中谷 真紀子; 古田 祐; 三田村 卓; 金野 陽輔; 武田 真人; 小林 範子; 工藤 正尊; 渡利 英道; 櫻木 範明, 日本婦人科腫瘍学会雑誌, 34, 3, 434, 434, 2016年06月
(公社)日本婦人科腫瘍学会, 日本語
- 検尿カップによる自己採尿検体を用いた子宮頸がん検診の実施可能性についての検討
第75回日本産科婦人科学会学術講演会, 2023年05月13日, ポスター発表
2023年05月12日 - 2023年05月14日
- 子宮体癌の分子分類診断システムの開発と新規治療標的の探索を志向したゲノム解析研究
科学研究費助成事業
2024年04月01日 - 2027年03月31日
渡利 英道; 畑中 佳奈子; 金野 陽輔; 畑中 豊; 朝野 拓史; 山崎 博之
日本学術振興会, 基盤研究(B), 北海道大学, 24K02581
